Asset Details
Do you wish to reserve the book?
Hit and lead criteria in drug discovery for infectious diseases of the developing world
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Hit and lead criteria in drug discovery for infectious diseases of the developing world
Do you wish to request the book?
Hit and lead criteria in drug discovery for infectious diseases of the developing world
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Hit and lead criteria in drug discovery for infectious diseases of the developing world
2015
Overview
The quality of the chemical starting points for small-molecule drug discovery is a key factor in improving the likelihood of clinical success. In this article, experts from several organizations involved in drug discovery for malaria, tuberculosis and neglected tropical diseases present disease-specific criteria for hits and leads, and discuss the underlying rationale.
Reducing the burden of infectious diseases that affect people in the developing world requires sustained collaborative drug discovery efforts. The quality of the chemical starting points for such projects is a key factor in improving the likelihood of clinical success, and so it is important to set clear go/no-go criteria for the progression of hit and lead compounds. With this in mind, the Japanese Global Health Innovative Technology (GHIT) Fund convened with experts from the Medicines for Malaria Venture, the Drugs for Neglected Diseases
initiative
and the TB Alliance, together with representatives from the Bill & Melinda Gates Foundation, to set disease-specific criteria for hits and leads for malaria, tuberculosis, visceral leishmaniasis and Chagas disease. Here, we present the agreed criteria and discuss the underlying rationale.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Animals
/ Communicable Diseases - drug therapy
/ Communicable Diseases - economics
/ Communicable Diseases - epidemiology
/ Developing Countries - economics
/ Drugs, Generic - therapeutic use
/ Humans
/ Malaria
/ Neglected Diseases - drug therapy
/ Neglected Diseases - economics
